Scancell is developing a vaccine platform that overcomes the present limitations of many therapeutic vaccines. The platform being developed is called an ImmunoBody® and uses a human monoclonal antibody as a vector to target key cells that are essential in stimulating immune responses. Due to the unique modular design of the ImmunoBody® , the stimulus delivered can be customised to make an effective immune response against a specific disease and a specific patient population.

This novel invention has been patent protected and is being developed into treatments for various cancers but also has the potential to be applied to the development of vaccines for chronic infections.

Scancell’s first clinical candidate drug , SCIB1, is being developed for the treatment of melanoma. It’s anti-tumour activity has already been validated in vivo and plans are now being put in place to allow the vaccine to be evaluated in patients.

SCIB2 is an anti-angiogenic vaccine that can be used alone for treatment of any angiogenic tumour or can be used in combination with site specific vaccines such as SCIB1 for the treatment of advanced cancer. The technology is also available for licensing to enhance the immune response to other novel targets.

© Scancell Limited, 2001-2007.